Altaris Capital Partners Acquires Kindeva Drug Delivery from 3M
May 1, 2020
Altaris Capital Partners has acquired Kindeva Drug Delivery L.P. (formerly 3M Drug Delivery Systems) from 3M Company for $650 million in a corporate carve-out transaction. Monroe Capital provided financing and an equity co-investment to support the deal, and 3M will retain a minority interest alongside Altaris as Kindeva operates independently to pursue growth and capital investments.
- Targets
- Kindeva Drug Delivery L.P.
- Sellers
- 3M Company
- Industry
- Medical Devices
- Location
- Minnesota, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Altaris Acquires Minaris Regenerative Medicine from Resonac
September 23, 2024
Healthcare Services
Altaris, LLC has acquired Minaris Regenerative Medicine from Resonac Corporation, making Minaris a wholly owned portfolio company of Altaris. Minaris is a cell therapy CDMO with six facilities across the United States, Germany and Japan and more than 500 employees; the deal advances Altaris' strategic initiative to build capabilities in cell and gene therapy manufacturing.
-
Kindeva Drug Delivery Acquires Summit Biosciences
January 18, 2024
Healthcare Services
Kindeva Drug Delivery, an operating company of Altaris, LLC, acquired Summit Biosciences, a specialized intranasal drug-delivery contract development and manufacturing organization (CDMO), from its founding family shareholders. The deal expands Kindeva’s drug-delivery capabilities with a new intranasal drug-delivery platform and adds Summit’s FDA- and EMA-approved cGMP facility in Lexington, Kentucky.
-
Altaris Combines Kindeva Drug Delivery and Meridian Medical Technologies
December 13, 2022
Medical Devices
Altaris has completed the combination of its portfolio companies Kindeva Drug Delivery and Meridian Medical Technologies into a single, global drug‑device CDMO that will operate under the Kindeva name. The combined company expands capabilities across parenteral, inhalation, transdermal and intradermal delivery formats; Milton Boyer (formerly Meridian CEO) will lead the combined business.
-
Altaris Capital Partners Acquires Meridian Medical Technologies from Pfizer
December 30, 2021
Medical Devices
Altaris Capital Partners has entered into an agreement to acquire Meridian Medical Technologies from Pfizer. Meridian, a pioneer in emergency response drug-device combination products and auto-injectors with facilities in St. Louis, Missouri and Columbia, Maryland and more than 750 employees, will become an Altaris portfolio company to expand the firm's capabilities in medical countermeasures and emergency response solutions.
-
Altaris Capital Partners Acquires Perrigo's Prescription Pharmaceuticals Business (Padagis)
March 1, 2021
Pharmaceuticals
Altaris Capital Partners has acquired Perrigo's prescription pharmaceuticals business for $1.55 billion and completed the carve-out, renaming the business Padagis. The business, a leader in generic prescription pharmaceuticals with more than 1,300 employees across six U.S. and Israeli locations and a portfolio of 200+ product families (800 SKUs), will be headquartered in the United States as a standalone company.
-
3M Acquires Acelity (and KCI) from Apax-led Consortium for $6.725B
October 11, 2019
Medical Devices
3M has completed the acquisition of Acelity and its KCI subsidiaries from funds advised by Apax Partners and consortium partners Canada Pension Plan Investment Board and the Public Sector Pension Investment Board for $6.725 billion. The transaction transfers Acelity — a global leader in advanced wound care and negative pressure wound therapy headquartered in San Antonio — to 3M, expanding 3M’s medical products capabilities.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.